Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020136879 - METHOD FOR PRESENTING EFFECTIVENESS OF IMMUNOTHERAPEUTIC AGENT FOR TREATING MALIGNANT TUMOR AND IMMUNOTHERAPEUTIC AGENT FOR TREATING MALIGNANT TUMOR

Publication Number WO/2020/136879
Publication Date 02.07.2020
International Application No. PCT/JP2018/048494
International Filing Date 28.12.2018
IPC
C12Q 1/18 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
02involving viable microorganisms
18Testing for antimicrobial activity of a material
A61K 39/395 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61P 35/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07K 16/18 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
C07K 16/28 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
G01N 33/574 2006.1
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
574for cancer
CPC
A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07K 16/18
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
C07K 16/46
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
46Hybrid immunoglobulins
C12Q 1/18
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms
02involving viable microorganisms
18Testing for antimicrobial activity of a material
Applicants
  • 国立大学法人大阪大学 OSAKA UNIVERSITY [JP]/[JP]
Inventors
  • 岩堀 幸太 IWAHORI, Kota
Agents
  • 特許業務法人三枝国際特許事務所 SAEGUSA & PARTNERS
Priority Data
Publication Language Japanese (JA)
Filing Language Japanese (JA)
Designated States
Title
(EN) METHOD FOR PRESENTING EFFECTIVENESS OF IMMUNOTHERAPEUTIC AGENT FOR TREATING MALIGNANT TUMOR AND IMMUNOTHERAPEUTIC AGENT FOR TREATING MALIGNANT TUMOR
(FR) PROCÉDÉ DE PRÉSENTATION DE L'EFFICACITÉ D'UN AGENT IMMUNOTHÉRAPEUTIQUE POUR LE TRAITEMENT D'UNE TUMEUR MALIGNE ET AGENT IMMUNOTHÉRAPEUTIQUE POUR LE TRAITEMENT D'UNE TUMEUR MALIGNE
(JA) 悪性腫瘍を治療するための免疫療法剤の有用性の提示方法及び悪性腫瘍を治療するための免疫療法剤
Abstract
(EN)
The present invention addresses the problem of presenting information required in companion diagnostics for predicting the effectiveness of an immunotherapeutic agent for individual patients. To solve the problem, the present invention provides a method for presenting the effectiveness of an immunotherapeutic agent for treating a malignant tumor for a patient having a malignant tumor, the method including the following steps 1 and 2. Step 1: a step for assessing whether tumor cells are damaged after directly or indirectly contacting, in vitro, peripheral blood mononuclear cells collected from the patient. Step 2: a step for presenting that the immunotherapeutic agent is effective for the patient if the assessment indicates that the tumor cells are damaged, and/or a step for presenting that the immunotherapeutic agent is not effective for the patient if the assessment indicates that the tumor cells are not damaged.
(FR)
La présente invention a pour objet la présentation d'informations requises dans des diagnostics associés pour prédire l'efficacité d'un agent immunothérapeutique pour des patients individuels. La solution selon la présente invention porte sur un procédé de présentation de l'efficacité d'un agent immunothérapeutique pour le traitement d'une tumeur maligne pour un patient ayant une tumeur maligne, le procédé comprenant les étapes 1 et 2 suivantes. Étape 1 : évaluer si des cellules tumorales sont endommagées après la mise en contact directe ou indirecte, in vitro, de cellules mononucléaires du sang périphérique prélevées chez le patient. Étape 2 : présenter l'efficacité de l'agent immunothérapeutique chez le patient si l'évaluation indique que les cellules tumorales ont été endommagées, et/ou présenter l'inéfficacité de l'agent immunothérapeutique chez le patient si l'évaluation indique que les cellules tumorales n'ont pas été endommagées.
(JA)
本発明は、個々の患者について免疫療法剤の有用性を予測するためのコンパニオン診断に必要な情報を提示することを一課題とする。 下記工程1、及び工程2を含む、悪性腫瘍を治療するための免疫療法剤について、前記悪性腫瘍を有する患者における有用性を提示する方法により前記課題を解決する:工程1:前記患者から採取された末梢血単核細胞と、直接、又は間接的にin vitroで接触した腫瘍細胞が傷害されているか否かを評価する工程、及び工程2:前記評価において前記腫瘍細胞が傷害されていることが示された場合に、前記患者に対して前記免疫療法剤が有用であることを提示する工程、及び/又は前記評価において前記腫瘍細胞が傷害されていないことが示された場合に、前記患者に対して前記免疫療法剤が有用でないことを提示する工程。
Latest bibliographic data on file with the International Bureau